Literature DB >> 2732784

The influence of ofloxacin versus trimethoprim-sulfamethoxazole on the aerobic flora in granulocytopenic subjects.

A Bartoloni1, R Fanci, A Orsi, D Aquilini, A Bosi, P Rossi Ferrini, F Paradisi.   

Abstract

Ofloxacin (300 mg twice a day) and trimethoprim-sulfamethoxazole (TMP-SMZ) (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day) were given prophylactically to 19 adult patients with acute leukemia undergoing induction chemotherapy. The influence of the two regimens on the bacterial aerobic flora was evaluated. Both of the prophylactic regimens conditioned the aerobic microflora of the patients. Both groups acquired new microorganisms, prevalently gram-positive cocci, but also gram-negative bacteria with the TMP-SMZ regimen. Both treatment groups acquired yeasts.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2732784     DOI: 10.1080/1120009x.1989.11738871

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  4 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 2.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

3.  Effects of broad-spectrum antibiotics on colonization of gastrointestinal tracts of mice by Candida albicans.

Authors:  G Samonis; H Anastassiadou; M Dassiou; Y Tselentis; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Prospective study of the impact of broad-spectrum antibiotics on the yeast flora of the human gut.

Authors:  G Samonis; A Gikas; P Toloudis; S Maraki; G Vrentzos; Y Tselentis; N Tsaparas; G Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-08       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.